Grace Therapeutics (GRCE) 10-Q 9 Feb 21 2021 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Dec. 31, 2020	Feb. 09, 2021
Document Information [Line Items]
Entity Registrant Name	Acasti Pharma Inc.
Entity Central Index Key	0001444192
Trading Symbol	acst
Current Fiscal Year End Date	--03-31
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Interactive Data Current	Yes
Entity Common Stock, Shares Outstanding (in shares)		179,495,705
Entity Shell Company	false
Document Type	10-Q
Document Period End Date	Dec. 31, 2020
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q3
Amendment Flag	false
Title of 12(b) Security	Common Shares, no par value per share

Condensed Consolidated Interim

Condensed Consolidated Interim Balance sheet (Current Period Unaudited) - USD ($) $ in Thousands	Dec. 31, 2020	Mar. 31, 2020
Current assets:
Cash and cash equivalents	$ 26,546	$ 14,240
Short-term investments	1,372
Receivables	619	546
Inventory	14
Assets held for sale	1,088	2,578
Deferred financing costs		121
Prepaid expenses	559	977
Total current assets	30,198	18,462
Right of Use Asset	105	147
Intangible assets		4,244
Total assets	30,303	22,853
Current liabilities:
Trade and other payables	2,143	7,319
Lease Liability	105	76
Total current liabilities	2,248	7,395
Derivative warrant liabilities	2,340	2,393
Lease Liability		71
Total liabilities	4,588	9,859
Equity:
Common shares	162,196	137,424
Additional paid-in capital	10,825	9,797
Accumulated other comprehensive loss	(6,934)	(7,887)
Accumulated deficit	(140,372)	(126,340)
Total shareholder’s equity (deficit)	25,715	12,994
Commitments and contingencies
Total liabilities and shareholders’ equity	$ 30,303	$ 22,853

Condensed Consolidated Interi_2

Condensed Consolidated Interim Statements of Loss and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2020	Dec. 31, 2019
Revenues from product sales	$ 81		$ 81
Cost of sales of products	(36)		(36)
Research and development expenses, net of government assistance	(678)	(3,912)	(3,720)	(14,056)
General and administrative expenses	(1,105)	(1,579)	(4,078)	(4,250)
Sales and marketing expenses	(226)	(655)	(1,076)	(2,101)
Impairment of Intangible assets			(3,706)
Impairment of Equipment			(1,584)
Loss from operating activities	(1,964)	(6,146)	(14,119)	(20,407)
Financial Income (expenses)	(1,256)	(5,977)	87	(21,721)
Net loss and total comprehensive loss	$ (3,220)	$ (12,123)	$ (14,032)	$ (42,128)
Basic and diluted loss per share (in dollars per share)	$ (0.03)	$ (0.14)	$ (0.15)	$ (0.51)
Weighted average number of shares outstanding (in shares)	110,467,167	86,767,312	95,376,935	82,817,283

Condensed Consolidated Interi_3

Condensed Consolidated Interim Statements of Changes in Shareholder's Equity (Unaudited) - USD ($) $ in Thousands	Common Stock [Member]	Additional Paid-in Capital [Member]	AOCI Attributable to Parent [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Mar. 31, 2019	78,132,734
Balance at Mar. 31, 2019	$ 110,857	$ 8,150	$ (7,135)	$ (100,827)	$ 11,045
Net loss and total comprehensive loss for the period				(8,846)	(8,846)
Cumulative translation adjustment			51		51
Stock based compensation	$ 2	250			252
Stock based compensation (in shares)	3,000
Balance (in shares) at Jun. 30, 2019	79,055,734
Balance at Jun. 30, 2019	$ 111,632	8,400	(7,084)	(109,673)	3,275
Shares issued as settlement (in shares)	900,000
Shares issued as settlement	$ 739				739
Warrants exercised (in shares)	20,000
Warrants exercised	$ 34				34
Balance (in shares) at Mar. 31, 2019	78,132,734
Balance at Mar. 31, 2019	$ 110,857	8,150	(7,135)	(100,827)	11,045
Net loss and total comprehensive loss for the period					(42,128)
Balance (in shares) at Dec. 31, 2019	89,057,819
Balance at Dec. 31, 2019	$ 136,494	9,335	(7,165)	(142,954)	(4,290)
Balance (in shares) at Jun. 30, 2019	79,055,734
Balance at Jun. 30, 2019	$ 111,632	8,400	(7,084)	(109,673)	3,275
Net loss and total comprehensive loss for the period				(21,158)	(21,158)
Cumulative translation adjustment			(64)		(64)
Stock based compensation	$ 20	650			670
Stock based compensation (in shares)	19,166
Balance (in shares) at Sep. 30, 2019	85,188,095
Balance at Sep. 30, 2019	$ 128,358	8,862	(7,148)	(130,831)	(759)
Warrants exercised (in shares)	6,113,195
Warrants exercised	$ 16,706	(188)			16,518
Net loss and total comprehensive loss for the period				(12,123)	(12,123)
Cumulative translation adjustment			(17)		(17)
Net proceeds from shares issued under the at-the-market (ATM) program (in shares)	2,914,356
Net proceeds from shares issued under the at-the-market (ATM) program	$ 6,002				6,002
Stock based compensation	$ 56	586			642
Stock based compensation (in shares)	32,460
Balance (in shares) at Dec. 31, 2019	89,057,819
Balance at Dec. 31, 2019	$ 136,494	9,335	(7,165)	(142,954)	(4,290)
Warrants exercised (in shares)	922,908
Warrants exercised	$ 2,078	(113)			1,965
Balance (in shares) at Mar. 31, 2020	90,209,449
Balance at Mar. 31, 2020	$ 137,424	9,797	(7,887)	(126,340)	12,994
Net loss and total comprehensive loss for the period				(4,666)	(4,666)
Cumulative translation adjustment			308		308
Net proceeds from shares issued under the at-the-market (ATM) program (in shares)	2,278,936
Net proceeds from shares issued under the at-the-market (ATM) program	$ 1,765				1,765
Stock based compensation		635			635
Balance (in shares) at Jun. 30, 2020	92,488,385
Balance at Jun. 30, 2020	$ 139,189	10,432	(7,579)	(131,006)	11,036
Balance (in shares) at Mar. 31, 2020	90,209,449
Balance at Mar. 31, 2020	$ 137,424	9,797	(7,887)	(126,340)	12,994
Net loss and total comprehensive loss for the period					(14,032)
Balance (in shares) at Dec. 31, 2020	156,073,767
Balance at Dec. 31, 2020	$ 162,196	10,825	(6,934)	(140,372)	25,715
Balance (in shares) at Jun. 30, 2020	92,488,385
Balance at Jun. 30, 2020	$ 139,189	10,432	(7,579)	(131,006)	11,036
Net loss and total comprehensive loss for the period				(6,146)	(6,146)
Cumulative translation adjustment			179		179
Net proceeds from shares issued under the at-the-market (ATM) program (in shares)	4,404,152
Net proceeds from shares issued under the at-the-market (ATM) program	$ 3,427				3,427
Stock based compensation	$ (46)	423			377
Stock based compensation (in shares)	(23,394)
Balance (in shares) at Sep. 30, 2020	96,869,143
Balance at Sep. 30, 2020	$ 142,570	10,855	(7,400)	(137,152)	8,873
Net loss and total comprehensive loss for the period				(3,220)	(3,220)
Cumulative translation adjustment			466		466
Net proceeds from shares issued under the at-the-market (ATM) program (in shares)	59,204,624
Net proceeds from shares issued under the at-the-market (ATM) program	$ 19,626				19,626
Stock based compensation		(30)			(30)
Balance (in shares) at Dec. 31, 2020	156,073,767
Balance at Dec. 31, 2020	$ 162,196	$ 10,825	$ (6,934)	$ (140,372)	$ 25,715

Condensed Consolidated Interi_4

Condensed Consolidated Interim Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2020	Dec. 31, 2019
Cash flows used in operating activities:
Net loss for the period	$ (3,220,000)	$ (12,123,000)	$ (14,032,000)	$ (42,128,000)
Adjustments:
Amortization of intangible assets		485,000	781,000	1,449,000
Depreciation of equipment		110,000	142,000	271,000
Impairment of intangible assets			3,706,000
Impairment of Equipment			1,584,000
Stock-based compensation	(30,000)	611,000	1,003,000	1,508,000
Change in fair value of warrant liabilities	1,098,000	5,882,000	(420,000)	21,756,000
Write off-of deferred financing costs of at-the-market (ATM) program			264,000
Accretion of interest on convertible debenture		30,000		106,000
Unrealized foreign exchange (gain) loss	(54,000)	(102,000)	(208,000)	(151,000)
Changes in non-cash working capital items	(2,009,000)	(2,007,000)	(5,404,000)	(2,870,000)
Changes in other assets	1,000	10,000	25,000	10,000
Net cash used in operating activities	(4,214,000)	(7,104,000)	(12,559,000)	(20,049,000)
Cash flows from (used in) investing activities:
Acquisition of equipment		(254,000)	(69,000)	(290,000)
Acquisition of investments	(1,372,000)	(32,000)	(1,393,000)	(2,063,000)
Maturity of investment		(61,000)	21,000	10,890,000
Net cash provided by (used in) investing activities	(1,372,000)	(347,000)	(1,441,000)	8,537,000
Cash flows used in financing activities:
Net proceeds from issuance of common shares under the at-the-market (ATM)	19,745,000	6,002,000	24,955,000	6,002,000
Deferred financing costs		(31,000)	(143,000)	(67,000)
Proceeds from exercise of warrants		1,081,000		7,733,000
Proceeds from exercise of stock options		33,000		45,000
Net cash provided by financing activities	19,745,000	7,117,000	24,812,000	13,713,000
Effect of exchange rate fluctuations on cash and cash equivalents	(1,843,000)	260,000	(1,993,000)	487,000
Translations effects on cash and cash equivalents related to reporting currency	2,678,000	345,000	3,487,000	208,000
Net increase in cash and cash equivalents	14,994,000	271,000	12,306,000	2,896,000
Cash and cash equivalents, beginning of period	11,552,000	19,496,000	14,240,000	16,871,000
Cash and cash equivalents, end of period	26,546,000	19,767,000	26,546,000	19,767,000
Cash and cash equivalents are comprised of:
Cash	7,104,000	6,874,000	7,104,000	6,874,000
Cash equivalents	$ 19,442,000	$ 12,893,000	$ 19,442,000	$ 12,893,000

Note 1 - Nature of Operation

Note 1 - Nature of Operation	9 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Nature of Operations [Text Block]	1. Nature of Operation: Acasti Pharma Inc. (“Acasti” or the “Corporation”) is incorporated under the Business Corporations Act (Québec) (formerly Part 1A 3009, H7E 2B5. In August 2020, 3 not In September 2020, no third

Note 2 - Summary of Significant

Note 2 - Summary of Significant Accounting Policies	9 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Significant Accounting Policies [Text Block]	2. Summary of significant accounting policies: Adoption of U.S. GAAP: These interim condensed consolidated financial statements of the Corporation have been prepared in accordance with generally accepted accounting principles in the United States of America (U.S. GAAP). Comparative figures, for the three nine December 31, 2019, Basis of presentation: These unaudited Interim Consolidated Financial Statements have been prepared using accounting policies consistent with those used in preparing the Corporation's March 31, 2020 3 The following summarizes the principal conditions or events relevant to the Corporation's going concern assessment, which primarily considers the period of one The Corporation has incurred operating losses and negative cash flows from operations since its inception. Prior to this quarter, there was substantial doubt regarding the Corporation's ability to realize its assets and discharge its liabilities and commitments in the ordinary course of business. During this quarter, the Corporation has raised net proceeds of $19.7 December 31, 2020 $27.9 $2.3 December 31, 2020 December 31, 2020, $7.9 The Corporation's ability to continue as a going concern is dependent upon its ability to achieve a successful strategic alternative and ultimately generate cashflows to meet its obligations. Due to the failure of the Corporation's Phase 3 not no not one no Use of estimates The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, income and expenses. Actual results may Estimates are based on management's best knowledge of current events and actions that management may Estimates and assumptions include the measurement of derivative warrant liabilities (note 7 11 5 6 14

Note 3 - Recent Accounting Pron

Note 3 - Recent Accounting Pronouncements	9 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Accounting Standards Update and Change in Accounting Principle [Text Block]	3. Recent Accounting Pronouncements In June 2016, 2016 13 326 2016 13 not 2016 13 December 15, 2022. not In August 2018, 2018 15 2018 15 December 15, 2019 not December 31, 2020.

Note 4 - Investments

Note 4 - Investments	9 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]	4. Short-term investments The Corporation holds various marketable securities, with maturities greater than 3 December 31, 2020 March 31, 2020 $ $ Term deposits issued in US currency earning interest at ranges between 0.30% and 0.40% and maturing on various dates from March 9, 2021 to June 22, 2021 536 - Term deposits issued in CAD currency earning interest at ranges between 0.62% and 0.67% and maturing on various dates from April 16, 2021 to June 22, 2021 836 - Total short-term investments 1,372 -

Note 5 - Impairment Loss Intang

Note 5 - Impairment Loss Intangible Assets	9 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Intangible Assets Disclosure [Text Block]	5. Impairment loss Intangible assets: The Corporation tests intangible assets for impairment should circumstances change or events occur that would indicate that the fair value of an asset may second 2021, 3 not 350, In prior years, the Corporation entered into agreements with Neptune Wellness Solutions Inc. (Neptune) pursuant to which the Corporation obtained a license and exercised its option under this license agreement to pay in advance all of the future royalties payable to Neptune. This license allows the Corporation to exploit the intellectual property rights in-order to develop novel active pharmaceutical ingredients into commercial products for the prescription drugs market. In assessing the magnitude of any impairment of the license the Corporation considered all available evidence including i) significant adverse impact from business climate due to Phase 3 not no no not, 3 $3,706 nine December 31, 2020, not six September 30, 2020.

Note 6 - Assets Held for Sale

Note 6 - Assets Held for Sale	9 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]	6. Assets held for sale During the period the Corporation committed to a plan and is actively marketing for sale Other assets and Equipment and has met the criteria for classification of assets held for sale: December 31, March 31, $ $ Other assets 712 668 Equipment 376 1,910 1,088 2,578 a. Other assets Other assets represent krill oil (RKO) held by the Company that was expected to be used in the conduct of R&D activities and commercial inventory scale up related to the development and commercialization of the CaPre drug. Given that the development of CaPre will no b. Equipment December 31, 2020 Cost Accumulated Impairment Net book $ $ $ $ Furniture and office equipment 17 (5 ) - 12 Computer equipment 136 (29 ) (54 ) 53 Laboratory equipment 749 (429 ) (171 ) 149 Production equipment 2,533 (1,012 ) (1,359 ) 162 3,435 (1,475 ) (1,584 ) 376 Equipment is made up of Laboratory, Production, Computer and Office equipment that was utilized in the development of CaPre. Similarly, to the intangible assets, the announcement of the failed Phase 3 3

Note 7 - Derivative Warrant Lia

Note 7 - Derivative Warrant Liabilities	9 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Derivative Instruments and Hedging Activities Disclosure [Text Block]	7. Derivative warrant liabilities: The warrants issued as part of the public offering of units composed of Common Shares and Common Share purchase warrants on May 9, 2018 May 14, 2018 Warrants issued as part of a public offering of units composed of Common Shares and Common Share purchase warrants on December 27, 2017 The derivative warrant liabilities are measured at fair value at each reporting period and the reconciliation of changes in fair value for the nine Warrant liabilities issued Warrant liabilities issued December 31, December 31, December 31, December 31, $ $ $ $ Balance – beginning of period 1,146 6,177 1,247 6,005 Amount transferred to Equity - (6,139 ) - (4,703 ) Change in fair value (100 ) 11,459 (320 ) 10,297 Translation effect 182 362 185 220 Balance – end of period 1,228 11,859 1,112 11,819 Fair value per share issuable USD$ 0.19 USD$ 1.80 USD$ 0.16 USD$ 1.67 The fair value of the derivative warrant liabilities was estimated using the Black-Scholes option pricing model and based on the following assumptions: Warrant liabilities issued Warrant liabilities issued December 31, March 31, December 31, March 31, Exercise price CAD$ 1.31 CAD$ 1.31 USD$ 1.26 USD$ 1.26 Share price CAD$ 0.42 CAD$ 0.53 USD$ 0.33 USD$ 0.38 Risk-free interest 0.58 % 0.66 % 0.36 % 0.37 % Estimated life (years) 2.35 3.11 1.99 2.74 Expected volatility 149.55 % 107.59 % 153.14 % 125.03 %

Note 8 - Capital and Other Comp

Note 8 - Capital and Other Components of Equity	9 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	8. Capital and other components of equity: (a) “At-the-market” sales agreement: On February 14, 2019, may $30 may 3 3% 4% June 29, 2020, may $75,000,000 no may may 3.0% During the nine December 31, 2020, 65.9 $24.8 $903. $0.39 $18 nine December 31, 2020, $264 (b) Shares issued as settlement: On May 10, 2019, 900,000 $0.82 $1.10 $48 $64. March 31, 2019 $786 $1,054 May 2019, $739 $990 (c) Warrants: The warrants of the Corporation are composed of the following as at December 31, 2020 March 31, 2020: December 31, 2020 March 31, 2020 Number Amount Number Amount $ $ Liability May 2018 public offering warrants 2018 (i) 6,593,750 1,228 6,593,750 1,146 Series December 2017 U.S. public offering warrants 2017 (ii) 7,072,962 1,112 7,072,962 1,247 13,666,712 2,340 13,666,712 2,393 Equity Public offering warrants Public offering Broker warrants May 2018(iii) 222,976 89 222,976 89 Series December 2017 US Broker warrants (iv) 259,121 161 259,121 161 Public offering warrants February 2017 (v) 1,723,934 631 1,723,934 631 2,206,031 881 2,206,031 881 (i) Warrant to acquire one $1.31, May 9, 2023. (ii) Warrant to acquire one $1.26, December 27, 2022. (iii) Warrant to acquire one $1.05, May 9, 2023. (iv) Warrant to acquire one $1.2625, December 19, 2022. (v) Warrant to acquire one $2.15, February 21, 2022. (d) Exercise of warrants: No three nine December 31, 2020. three nine December 31, 2019, Three-month periods ended Nine-month periods ended December 31, 2019 December 31, 2019 Number exercised Proceeds Number exercised Proceeds $ $ May 2018 over-allotment Warrants 2018 75,000 75 3,594,350 3,586 Series December 2017 US Public offering Warrants 2017 403,808 479 2,676,611 3,382 Public offering warrants February 2017 94,100 153 180,100 292 Public offering Broker warrants May 2018 200,000 158 325,000 257 Contingent warrants private placement 2017 150,000 216 150,000 216 922,908 1,081 6,926,061 7,733 In 2019, 235,929, 52,288 December 2017 136,013

Note 9 - Government Assistance

Note 9 - Government Assistance	9 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Government Assistance [Text Block]	9. Government assistance: Government assistance is comprised of a government grant from the Canadian federal government and research and development investment tax credits receivable from the Quebec provincial government, which relate to qualifiable research and development expenditures under the applicable tax laws. The amounts recorded as receivables are subject to a government tax audit and the final amounts received may nine December 31, 2020 December 31, 2019, $84 $75, In September 2019, $750,000 nine December 31, 2020 $79 In October 2020, $750,000 $326,357. Acasti Pharma inc. Notes to Consolidated Interim Financial Statements (Unaudited) Three-month and nine December 31, 2020 2019

Note 10 - Revenues

Note 10 - Revenues	9 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Revenue from Contract with Customer [Text Block]	10. Revenues: In October 2020, 19

Note 11 - Financial Income (Exp

Note 11 - Financial Income (Expenses)	9 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Other Income and Other Expense Disclosure [Text Block]	11. Financial Income (expenses): Three-month periods ended Nine-month periods ended December 31, December 31, December 31, December 31, $ $ $ $ Foreign exchange gain (loss) (196 ) (88 ) (146 ) (51 ) Interest payable on convertible debenture - (23 ) - (83 ) Accretion of interest on convertible debenture - (30 ) - (106 ) Write off-of deferred financing fees related to at-the-market (ATM) program - - (264 ) - Change in fair value of warrant liabilities (1,098 ) (5,882 ) 420 (21,756 ) Interest income 38 46 77 275 Financial income (expenses) (1,256 ) (5,977 ) 87 (21,721 )

Note 12 - Stock Based Compensat

Note 12 - Stock Based Compensation	9 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Share-based Payment Arrangement [Text Block]	12. Stock based compensation: At December 31, 2020 September 30, 2020. not may 11,719.910 15% April 9, 2019, 14,533,881 15% August 26, 2020. ten twelve 12 thirty-six 36 The total number of shares issued to any one twelve 2% not twelve 2% one twelve 2% The following table summarizes information about activities within the stock option plan for the nine December 31, 2020 December 31, 2019 Weighted average Number of Weighted average Number of CAD $ CAD $ Outstanding at beginning of period 1.00 9,936,486 1.25 4,046,677 Granted - - 1.39 2,304,517 Exercised - - 1.11 (54,625 ) Forfeited 0.84 (1,787,809 ) 1.04 (11,917 ) Expired - - 6.50 (7,500 ) Outstanding at end of period 1.03 8,148,677 1.30 6,277,152 Exercisable at end of period 1.18 5,296,811 1.39 2,917,543 No three nine December 31, 2020. three nine December 31, 2019 nine December 31, 2019 Exercise price $ 1.39 Share price $ 2.02 Dividend - Risk-free interest 1.60 % Estimated life (years) 5.78 Expected volatility 89.70 % At the grant date (which for some options occurs after issuance date upon shareholder approval of the options), the weighted average fair value of the options granted to employees and directors during the nine December 31, 2019 $1.58. No Compensation expense recognized under the stock option plan for the three December 31, 2020 2019 Three-month periods ended Nine-month periods ended December 31, December 31, December 31, December 31, $ $ $ $ Research and development expenses 58 131 304 350 General and administrative expenses 174 386 706 959 Sales and marketing expenses (262 ) 94 (7 ) 199 (30 ) 611 1,003 1,508 Stock-based compensation payment transactions and broker warrants: The fair value of stock-based compensation transactions is measured using the Black-Scholes option pricing model. Measurement inputs include share price on measurement date, exercise price of the instrument, expected volatility (based on weighted average historic volatility for a duration equal to the weighted average life of the instruments, life based on the average of the vesting and contractual periods for employee awards as minimal prior exercises of options in which to establish historical exercise experience; contractual life for broker warrants), and the risk-free interest rate (based on government bonds). Service and performance conditions attached to the transactions, if any, are not not may may not

Note 13 - Supplemental Cash Flo

Note 13 - Supplemental Cash Flow Disclosure	9 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Cash Flow, Supplemental Disclosures [Text Block]	13. Supplemental cash flow disclosure: (a) Changes in non-cash operating items: Three-month periods ended Nine-month periods ended December 31, December 31, December 31, December 31, $ $ $ $ Receivables 27 (237 ) (20 ) (10 ) Inventory (14 ) - (14 ) - Prepaid expenses (23 ) (1,074 ) 521 (518 ) Trade and other payables (1,999 ) (696 ) (5,891 ) (2,342 ) (2,009 ) (2,007 ) (5,404 ) (2,870 ) (b) Non-cash transactions: Three-month periods ended Nine-month periods ended December 31, December 31, December 31, December 31, $ $ $ $ Equipment included in trade and other payables - 9 - 9 ATM transaction costs included in trade and other payables 118 - 118 - Shares issued as settlement - - - 741 Fair value of derivative warrants liability reclassified to Equity - 868 - 10,962 Interest payable included in trade and other payables - 31 - 31

Note 14 - Commitments and Conti

Note 14 - Commitments and Contingencies	9 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	14. Commitments and contingencies: (a) Take or pay contract On October 25, 2019, $3.1 4th 2021. December 31, 2020, $2.8 no may (b) Success fees On September 23, 2020 (c) Retention agreements In October 2020 The Retention Agreements provide that the Corporation will pay the CEO an employment retention incentive of $100 April 30, 2021 third In addition, the Retention Agreements also provide that the Corporation will pay each of the CEO and COO an amount of up to $125

Note 15 - Comparative Figures

Note 15 - Comparative Figures	9 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Accounting Changes and Error Corrections [Text Block]	15. Comparative figures Certain comparative figures in the nine three December 31, 2019,

Note 16 - Subsequent Events

Note 16 - Subsequent Events	9 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Subsequent Events [Text Block]	16. Subsequent events: In January 2021, 23.4 $7.9 $8.1

Significant Accounting Policies

Significant Accounting Policies (Policies)	9 Months Ended
	Dec. 31, 2020
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Adoption of U.S. GAAP: These interim condensed consolidated financial statements of the Corporation have been prepared in accordance with generally accepted accounting principles in the United States of America (U.S. GAAP). Comparative figures, for the three nine December 31, 2019, Basis of presentation: These unaudited Interim Consolidated Financial Statements have been prepared using accounting policies consistent with those used in preparing the Corporation's March 31, 2020 3 The following summarizes the principal conditions or events relevant to the Corporation's going concern assessment, which primarily considers the period of one The Corporation has incurred operating losses and negative cash flows from operations since its inception. Prior to this quarter, there was substantial doubt regarding the Corporation's ability to realize its assets and discharge its liabilities and commitments in the ordinary course of business. During this quarter, the Corporation has raised net proceeds of $19.7 December 31, 2020 $27.9 $2.3 December 31, 2020 December 31, 2020, $7.9 The Corporation's ability to continue as a going concern is dependent upon its ability to achieve a successful strategic alternative and ultimately generate cashflows to meet its obligations. Due to the failure of the Corporation's Phase 3 not no not one no
Use of Estimates, Policy [Policy Text Block]	Use of estimates The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, income and expenses. Actual results may Estimates are based on management's best knowledge of current events and actions that management may Estimates and assumptions include the measurement of derivative warrant liabilities (note 7 11 5 6 14

Note 4 - Investments (Tables)

Note 4 - Investments (Tables)	9 Months Ended
	Dec. 31, 2020
Notes Tables
Marketable Securities [Table Text Block]	December 31, 2020 March 31, 2020 $ $ Term deposits issued in US currency earning interest at ranges between 0.30% and 0.40% and maturing on various dates from March 9, 2021 to June 22, 2021 536 - Term deposits issued in CAD currency earning interest at ranges between 0.62% and 0.67% and maturing on various dates from April 16, 2021 to June 22, 2021 836 - Total short-term investments 1,372 -

Note 6 - Assets Held for Sale (

Note 6 - Assets Held for Sale (Tables)	9 Months Ended
	Dec. 31, 2020
Notes Tables
Disposal Groups, Including Discontinued Operations [Table Text Block]	December 31, March 31, $ $ Other assets 712 668 Equipment 376 1,910 1,088 2,578 December 31, 2020 Cost Accumulated Impairment Net book $ $ $ $ Furniture and office equipment 17 (5 ) - 12 Computer equipment 136 (29 ) (54 ) 53 Laboratory equipment 749 (429 ) (171 ) 149 Production equipment 2,533 (1,012 ) (1,359 ) 162 3,435 (1,475 ) (1,584 ) 376

Note 7 - Derivative Warrant L_2

Note 7 - Derivative Warrant Liabilities (Tables)	9 Months Ended
	Dec. 31, 2020
Notes Tables
Schedule of Derivative Liabilities at Fair Value [Table Text Block]	Warrant liabilities issued Warrant liabilities issued December 31, December 31, December 31, December 31, $ $ $ $ Balance – beginning of period 1,146 6,177 1,247 6,005 Amount transferred to Equity - (6,139 ) - (4,703 ) Change in fair value (100 ) 11,459 (320 ) 10,297 Translation effect 182 362 185 220 Balance – end of period 1,228 11,859 1,112 11,819 Fair value per share issuable USD$ 0.19 USD$ 1.80 USD$ 0.16 USD$ 1.67
Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]	Warrant liabilities issued Warrant liabilities issued December 31, March 31, December 31, March 31, Exercise price CAD$ 1.31 CAD$ 1.31 USD$ 1.26 USD$ 1.26 Share price CAD$ 0.42 CAD$ 0.53 USD$ 0.33 USD$ 0.38 Risk-free interest 0.58 % 0.66 % 0.36 % 0.37 % Estimated life (years) 2.35 3.11 1.99 2.74 Expected volatility 149.55 % 107.59 % 153.14 % 125.03 %

Note 8 - Capital and Other Co_2

Note 8 - Capital and Other Components of Equity (Tables)	9 Months Ended
	Dec. 31, 2020
Notes Tables
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	December 31, 2020 March 31, 2020 Number Amount Number Amount $ $ Liability May 2018 public offering warrants 2018 (i) 6,593,750 1,228 6,593,750 1,146 Series December 2017 U.S. public offering warrants 2017 (ii) 7,072,962 1,112 7,072,962 1,247 13,666,712 2,340 13,666,712 2,393 Equity Public offering warrants Public offering Broker warrants May 2018(iii) 222,976 89 222,976 89 Series December 2017 US Broker warrants (iv) 259,121 161 259,121 161 Public offering warrants February 2017 (v) 1,723,934 631 1,723,934 631 2,206,031 881 2,206,031 881
Schedule of Stockholders' Equity Note, Warrants or Rights Exercised [Table Text Block]	Three-month periods ended Nine-month periods ended December 31, 2019 December 31, 2019 Number exercised Proceeds Number exercised Proceeds $ $ May 2018 over-allotment Warrants 2018 75,000 75 3,594,350 3,586 Series December 2017 US Public offering Warrants 2017 403,808 479 2,676,611 3,382 Public offering warrants February 2017 94,100 153 180,100 292 Public offering Broker warrants May 2018 200,000 158 325,000 257 Contingent warrants private placement 2017 150,000 216 150,000 216 922,908 1,081 6,926,061 7,733

Note 11 - Financial Income (E_2

Note 11 - Financial Income (Expenses) (Tables)	9 Months Ended
	Dec. 31, 2020
Notes Tables
Schedule of Other Nonoperating Income (Expense) [Table Text Block]	Three-month periods ended Nine-month periods ended December 31, December 31, December 31, December 31, $ $ $ $ Foreign exchange gain (loss) (196 ) (88 ) (146 ) (51 ) Interest payable on convertible debenture - (23 ) - (83 ) Accretion of interest on convertible debenture - (30 ) - (106 ) Write off-of deferred financing fees related to at-the-market (ATM) program - - (264 ) - Change in fair value of warrant liabilities (1,098 ) (5,882 ) 420 (21,756 ) Interest income 38 46 77 275 Financial income (expenses) (1,256 ) (5,977 ) 87 (21,721 )

Note 12 - Stock Based Compens_2

Note 12 - Stock Based Compensation (Tables)	9 Months Ended
	Dec. 31, 2020
Notes Tables
Share-based Payment Arrangement, Option, Activity [Table Text Block]	December 31, 2020 December 31, 2019 Weighted average Number of Weighted average Number of CAD $ CAD $ Outstanding at beginning of period 1.00 9,936,486 1.25 4,046,677 Granted - - 1.39 2,304,517 Exercised - - 1.11 (54,625 ) Forfeited 0.84 (1,787,809 ) 1.04 (11,917 ) Expired - - 6.50 (7,500 ) Outstanding at end of period 1.03 8,148,677 1.30 6,277,152 Exercisable at end of period 1.18 5,296,811 1.39 2,917,543
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	December 31, 2019 Exercise price $ 1.39 Share price $ 2.02 Dividend - Risk-free interest 1.60 % Estimated life (years) 5.78 Expected volatility 89.70 %
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]	Three-month periods ended Nine-month periods ended December 31, December 31, December 31, December 31, $ $ $ $ Research and development expenses 58 131 304 350 General and administrative expenses 174 386 706 959 Sales and marketing expenses (262 ) 94 (7 ) 199 (30 ) 611 1,003 1,508

Note 13 - Supplemental Cash F_2

Note 13 - Supplemental Cash Flow Disclosure (Tables)	9 Months Ended
	Dec. 31, 2020
Notes Tables
Cash Flow, Operating Capital [Table Text Block]	Three-month periods ended Nine-month periods ended December 31, December 31, December 31, December 31, $ $ $ $ Receivables 27 (237 ) (20 ) (10 ) Inventory (14 ) - (14 ) - Prepaid expenses (23 ) (1,074 ) 521 (518 ) Trade and other payables (1,999 ) (696 ) (5,891 ) (2,342 ) (2,009 ) (2,007 ) (5,404 ) (2,870 )
Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]	Three-month periods ended Nine-month periods ended December 31, December 31, December 31, December 31, $ $ $ $ Equipment included in trade and other payables - 9 - 9 ATM transaction costs included in trade and other payables 118 - 118 - Shares issued as settlement - - - 741 Fair value of derivative warrants liability reclassified to Equity - 868 - 10,962 Interest payable included in trade and other payables - 31 - 31

Note 1 - Nature of Operation (D

Note 1 - Nature of Operation (Details Textual) - USD ($) $ in Thousands	Dec. 31, 2020	Mar. 31, 2020
Liabilities, Current, Total	$ 2,248	$ 7,395

Note 2 - Summary of Significa_2

Note 2 - Summary of Significant Accounting Policies (Details Textual) - USD ($)	1 Months Ended	3 Months Ended	9 Months Ended
	Jan. 31, 2021	Dec. 31, 2020	Dec. 31, 2020	Mar. 31, 2020
Cash, Cash Equivalents, and Short-term Investments, Total		$ 27,900,000	$ 27,900,000
Liabilities, Current, Total		2,248,000	2,248,000	$ 7,395,000
At-the-market Offering [Member]
Proceeds from Issuance of Common Stock, Net		$ 19,700,000	$ 24,800,000
At-the-market Offering [Member] | Subsequent Event [Member]
Proceeds from Issuance of Common Stock, Net	$ 7,900,000

Note 4 - Investments - Marketab

Note 4 - Investments - Marketable Securities (Details) $ in Thousands, $ in Thousands	Dec. 31, 2020USD ($)	Dec. 31, 2020CAD ($)	Mar. 31, 2020USD ($)	Mar. 31, 2020CAD ($)
Total Investments - US	$ 1,372
Total short-term investments	1,372
Deposits [Member]
Total Investments - US	536
Total short-term investments	$ 536
Canadian Deposits [Member]
Total Investments - US		$ 836
Total short-term investments		$ 836

Note 4 - Investments - Market_2

Note 4 - Investments - Marketable Securities (Details) (Parentheticals)	Dec. 31, 2020	Mar. 31, 2020
Deposits [Member] | Minimum [Member]
Investment, interest	0.30%	0.30%
Investment, maturity date	Mar. 9, 2021	Mar. 9, 2021
Deposits [Member] | Maximum [Member]
Investment, interest	0.40%	0.40%
Investment, maturity date	Jun. 22, 2021	Jun. 22, 2021
Canadian Deposits [Member] | Minimum [Member]
Investment, interest	0.62%	0.62%
Investment, maturity date	Apr. 16, 2021	Apr. 16, 2021
Canadian Deposits [Member] | Maximum [Member]
Investment, interest	0.67%	0.67%
Investment, maturity date	Jun. 22, 2021	Jun. 22, 2021

Note 5 - Impairment Loss Inta_2

Note 5 - Impairment Loss Intangible Assets (Details Textual) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2020	Dec. 31, 2019
Impairment of Intangible Assets, Finite-lived			$ 3,706

Note 6 - Assets Held for Sale -

Note 6 - Assets Held for Sale - Summary of Assets Held for Sale (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2020	Dec. 31, 2019	Mar. 31, 2020
Disposal Group, Including Discontinued Operation, Assets, Current, Total	$ 1,088		$ 1,088		$ 2,578
Equipment held-for-sale, impairment loss			(1,584)
Disposal Group, Held-for-sale, Not Discontinued Operations [Member]
Other assets	712		712		668
Equipment	376		376		1,910
Disposal Group, Including Discontinued Operation, Assets, Current, Total	1,088		1,088		$ 2,578
Equipment held-for-sale, cost	3,435		3,435
Equipment held-for-sale, accumulated depreciation	(1,475)		(1,475)
Equipment held-for-sale, impairment loss			(1,584)
Equipment held-for-sale, net book value	376		376
Disposal Group, Held-for-sale, Not Discontinued Operations [Member] | Furniture and Office Equipment [Member]
Equipment held-for-sale, cost	17		17
Equipment held-for-sale, accumulated depreciation	(5)		(5)
Equipment held-for-sale, impairment loss
Equipment held-for-sale, net book value	12		12
Disposal Group, Held-for-sale, Not Discontinued Operations [Member] | Computer Equipment [Member]
Equipment held-for-sale, cost	136		136
Equipment held-for-sale, accumulated depreciation	(29)		(29)
Equipment held-for-sale, impairment loss			(54)
Equipment held-for-sale, net book value	53		53
Disposal Group, Held-for-sale, Not Discontinued Operations [Member] | Laboratory Equipment [Member]
Equipment held-for-sale, cost	749		749
Equipment held-for-sale, accumulated depreciation	(429)		(429)
Equipment held-for-sale, impairment loss			(171)
Equipment held-for-sale, net book value	149		149
Disposal Group, Held-for-sale, Not Discontinued Operations [Member] | Production Equipment [Member]
Equipment held-for-sale, cost	2,533		2,533
Equipment held-for-sale, accumulated depreciation	(1,012)		(1,012)
Equipment held-for-sale, impairment loss			(1,359)
Equipment held-for-sale, net book value	$ 162		$ 162

Note 7 - Derivative Warrant L_3

Note 7 - Derivative Warrant Liabilities - Changes in Fair Value (Details) - USD ($) $ / shares in Units, $ in Thousands	9 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Warrants Issued in May 2018 [Member]
Balance – beginning of period	$ 1,146	$ 6,177
Amount transferred to Equity		(6,139)
Change in fair value	(100)	11,459
Translation effect	182	362
Balance – end of period	$ 1,228	$ 11,859
Fair value per share issuable (in dollars per share)	$ 0.19	$ 1.80
Warrants Issued December 27, 2017 [Member]
Balance – beginning of period	$ 1,247	$ 6,005
Amount transferred to Equity		(4,703)
Change in fair value	(320)	10,297
Translation effect	185	220
Balance – end of period	$ 1,112	$ 11,819
Fair value per share issuable (in dollars per share)	$ 0.16	$ 1.67

Note 7 - Derivative Warrant L_4

Note 7 - Derivative Warrant Liabilities - Assumptions (Details)	Sep. 30, 2020	Mar. 31, 2020
Measurement Input, Exercise Price [Member] | Warrants Issued in May 2018 [Member]
Derivative warrant liability, measurement input	1.31	1.31
Measurement Input, Exercise Price [Member] | Warrants Issued December 27, 2017 [Member]
Derivative warrant liability, measurement input	1.26	1.26
Measurement Input, Share Price [Member] | Warrants Issued in May 2018 [Member]
Derivative warrant liability, measurement input	0.42	0.53
Measurement Input, Share Price [Member] | Warrants Issued December 27, 2017 [Member]
Derivative warrant liability, measurement input	0.33	0.38
Measurement Input, Risk Free Interest Rate [Member] | Warrants Issued in May 2018 [Member]
Derivative warrant liability, measurement input	0.0058	0.0066
Measurement Input, Risk Free Interest Rate [Member] | Warrants Issued December 27, 2017 [Member]
Derivative warrant liability, measurement input	0.0036	0.0037
Measurement Input, Expected Term [Member] | Warrants Issued in May 2018 [Member]
Derivative warrant liability, measurement input	2.35	3.11
Measurement Input, Expected Term [Member] | Warrants Issued December 27, 2017 [Member]
Derivative warrant liability, measurement input	1.99	2.74
Measurement Input, Price Volatility [Member] | Warrants Issued in May 2018 [Member]
Derivative warrant liability, measurement input	1.4955	1.0759
Measurement Input, Price Volatility [Member] | Warrants Issued December 27, 2017 [Member]
Derivative warrant liability, measurement input	1.5314	1.2503

Note 8 - Capital and Other Co_3

Note 8 - Capital and Other Components of Equity (Details Textual) $ / shares in Units, $ / shares in Units, $ in Thousands	Jun. 29, 2020USD ($)	May 10, 2019USD ($)shares	May 10, 2019CAD ($)$ / sharesshares	Feb. 14, 2019USD ($)	May 31, 2019USD ($)	May 31, 2019CAD ($)	Dec. 31, 2020USD ($)shares	Dec. 31, 2019USD ($)shares	Jun. 30, 2019USD ($)	Dec. 31, 2020USD ($)$ / sharesshares	Dec. 31, 2019USD ($)shares	Mar. 31, 2019USD ($)	Mar. 31, 2019CAD ($)	Dec. 31, 2020$ / sharesshares	Dec. 31, 2020$ / sharesshares	May 10, 2019$ / shares
At-the-market Sales Agreement, Common Stock, Maximum Amount | $	$ 75,000,000			$ 30,000,000
At-the-market Sales Agreement, Term (Year)				3 years
At-the-market Sales Agreement, Underwriter Fees, Percentage of Sales	3.00%
Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs | $										$ 18,000
Write Off of Deferred Financing Costs of At-the-Market Program | $										$ 264,000
Stock Issued During Period, Value, Settlements | $									$ 739,000
Class of Warrant or Right, Exercised During Period (in shares)								922,908			6,926,061
Warrants Issued in May 2018 [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)														1	1
Class of Warrant or Right, Exercise Price of Warrants or Rights (in CAD per share) | $ / shares														$ 1.31
Warrants Issued December 27, 2017 [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)														1	1
Class of Warrant or Right, Exercise Price of Warrants or Rights (in CAD per share) | $ / shares															$ 1.26
Class of Warrant or Right, Exercised During Period (in shares)								403,808			2,676,611
Class of Warrant or Right, Exercised During Period, Cashless (in shares)										52,288
Stock Issued During Period, Shares, Warrant Excercises (in shares)										136,013
Broker Warrants Issued May 2018 [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)														1	1
Class of Warrant or Right, Exercise Price of Warrants or Rights (in CAD per share) | $ / shares														$ 1.05
Class of Warrant or Right, Exercised During Period (in shares)								200,000			325,000
Broker Warrants Issued December 2017 [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)														1	1
Class of Warrant or Right, Exercise Price of Warrants or Rights (in CAD per share) | $ / shares															$ 1.2625
Class of Warrant or Right, Exercised During Period, Cashless (in shares)										235,929
Warrants Issued in Connection with Public Offering February 2017 [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)														1	1
Class of Warrant or Right, Exercise Price of Warrants or Rights (in CAD per share) | $ / shares														$ 2.15
Class of Warrant or Right, Exercised During Period (in shares)								94,100			180,100
Warrants [Member]
Class of Warrant or Right, Exercised During Period (in shares)							0			0
General and Administrative Expense [Member]
Litigation Settlement, Expense												$ 786,000	$ 1,054
Former Chief Executive Officer [Member]
Stock Issued During Period, Shares, Settlements (in shares)		900,000	900,000
Shares Issued, Price Per Share (in dollars per share) | (per share)			$ 1.10													$ 0.82
Legal Fees		$ 48,000	$ 64
Stock Issued During Period, Value, Settlements					$ 739,000	$ 990
At-the-market Offering [Member]
Stock Issued During Period, Shares, New Issues (in shares)										65,900,000
Proceeds from Issuance of Common Stock, Net | $							$ 19,700,000			$ 24,800,000
Commission Costs Related to Share Sale | $										$ 903,000
Sale of Stock, Average Price Per Share (in dollars per share) | $ / shares										$ 0.39
Minimum [Member]
At-the-market Sales Agreement, Underwriter Fees, Percentage of Sales				3.00%
Maximum [Member]
At-the-market Sales Agreement, Underwriter Fees, Percentage of Sales				4.00%

Note 8 - Capital and Other Co_4

Note 8 - Capital and Other Components of Equity - Warrants (Details) - USD ($) $ in Thousands		Dec. 31, 2020	Mar. 31, 2020
Number outstanding (in shares)		2,206,031	2,206,031
Amount		$ 881	$ 881
Over-Allotment Option Warrants Issued in May 2018 [Member]
Number outstanding (in shares)	[1]	6,593,750	6,593,750
Amount	[1]	$ 1,228	$ 1,146
Warrants Issued December 27, 2017 [Member]
Number outstanding (in shares)	[2]	7,072,962	7,072,962
Amount	[2]	$ 1,112	$ 1,247
Derivative Liability Warrants [Member]
Number outstanding (in shares)		13,666,712	13,666,712
Amount		$ 2,340	$ 2,393
Broker Warrants Issued May 2018 [Member]
Number outstanding (in shares)	[3]	222,976	222,976
Amount	[3]	$ 89	$ 89
Broker Warrants Issued December 2017 [Member]
Number outstanding (in shares)	[4]	259,121	259,121
Amount	[4]	$ 161	$ 161
Warrants Issued in Connection with Public Offering February 2017 [Member]
Number outstanding (in shares)	[5]	1,723,934	1,723,934
Amount	[5]	$ 631	$ 631
[1]	Warrant to acquire one Common Share at an exercise price of CAD $1.31, expiring on May 9, 2023.
[2]	Warrant to acquire one Common Share at an exercise price of $1.26, expiring on December 27, 2022.
[3]	Warrant to acquire one Common Share o at an exercise price of CAD $1.05, expiring on May 9, 2023.
[4]	Warrant to acquire one Common Share at an exercise price of $1.2625, expiring on December 19, 2022.
[5]	Warrant to acquire one Common Share at an exercise price of CAD $2.15, expiring on February 21, 2022.

Note 8 - Capital and Other Co_5

Note 8 - Capital and Other Components of Equity - Warrant Exercises (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2020	Dec. 31, 2019
Number exercised (in shares)		922,908		6,926,061
Proceeds		$ 1,081		$ 7,733
Over-Allotment Option Warrants Issued in May 2018 [Member]
Number exercised (in shares)		75,000		3,594,350
Proceeds		$ 75		$ 3,586
Warrants Issued December 27, 2017 [Member]
Number exercised (in shares)		403,808		2,676,611
Proceeds		$ 479		$ 3,382
Warrants Issued in Connection with Public Offering February 2017 [Member]
Number exercised (in shares)		94,100		180,100
Proceeds		$ 153		$ 292
Broker Warrants Issued May 2018 [Member]
Number exercised (in shares)		200,000		325,000
Proceeds		$ 158		$ 257
Warrants Issued in Connection with Private Placement [Member]
Number exercised (in shares)		150,000		150,000
Proceeds		$ 216		$ 216

Note 9 - Government Assistance

Note 9 - Government Assistance (Details Textual) $ in Thousands, $ in Thousands	1 Months Ended		9 Months Ended
	Oct. 31, 2020CAD ($)	Sep. 30, 2019CAD ($)	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)
Proceeds from NRC IRAP			$ 79
Maximum [Member]
Award in Non-dilutive and Non-repayable Funding From NRC IRAP	$ 326,357	$ 750,000
Research and Development Expense [Member]
Government Assistance			$ 84	$ 75

Note 11 - Financial Income (E_3

Note 11 - Financial Income (Expenses) - Financial Expenses (Details) - USD ($)	3 Months Ended		9 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2020	Dec. 31, 2019
Foreign exchange gain (loss)	$ (196,000)	$ (88,000)	$ (146,000)	$ (51,000)
Interest payable on convertible debenture		(23,000)		(83,000)
Accretion of interest on convertible debenture		(30,000)		(106,000)
Write off-of deferred financing fees related to at-the-market (ATM) program			(264,000)
Change in fair value of warrant liabilities	(1,098,000)	(5,882,000)	420,000	(21,756,000)
Interest income	38,000	46,000	77,000	275,000
Financial income (expenses)	$ (1,256,000)	$ (5,977,000)	$ 87,000	$ (21,721,000)

Note 12 - Stock Based Compens_3

Note 12 - Stock Based Compensation (Details Textual) - Stock Option Plan [Member] - $ / shares	Aug. 26, 2020	Aug. 27, 2019	Apr. 09, 2019	Dec. 31, 2020	Dec. 31, 2020	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)	14,533,881		11,719.91
Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum	15.00%		15.00%
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)	10 years
Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum Per Person		2.00%
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)				0	0	2,304,517
Consultant [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum Per Person		2.00%
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)					0
Related Party [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum Per Person		2.00%
Directors and Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in CAD per share)					$ 1.58

Note 12 - Stock Based Compens_4

Note 12 - Stock Based Compensation - Activities Within the Stock Option Plan (Details) - Stock Option Plan [Member] - $ / shares	3 Months Ended	9 Months Ended
	Dec. 31, 2020	Dec. 31, 2020	Dec. 31, 2019
Outstanding, weighted average exercise price (in CAD per share)		$ 1	$ 1.25
Outstanding, number of options (in shares)		9,936,486	4,046,677
Granted, weighted average exercise price (in CAD per share)			$ 1.39
Granted, number of options (in shares)	0	0	2,304,517
Exercised, weighted average exercise price (in CAD per share)			$ 1.11
Exercised, number of options (in shares)			(54,625)
Forfeited, weighted average exercise price (in CAD per share)		$ 0.84	$ 1.04
Forfeited, number of options (in shares)		(1,787,809)	(11,917)
Expired (in CAD per share)			$ 6.50
Expired (in shares)			(7,500)
Outstanding, weighted average exercise price (in CAD per share)	$ 1.03	$ 1.03	$ 1.30
Outstanding, number of options (in shares)	8,148,677	8,148,677	6,277,152
Exercisable, weighted average exercise price (in CAD per share)	$ 1.18	$ 1.18	$ 1.39
Exercisable, number of options (in shares)	5,296,811	5,296,811	2,917,543

Note 12 - Stock-based Compensat

Note 12 - Stock-based Compensation - Assumptions (Details) - Share-based Payment Arrangement, Option [Member]	9 Months Ended
	Dec. 31, 2019$ / shares
Exercise price (in CAD per share)	$ 1.39
Share price (in CAD per share)	$ 2.02
Dividend
Risk-free interest	1.60%
Estimated life (years) (Year)	5 years 284 days
Expected volatility	89.70%

Note 12 - Stock Based Compens_5

Note 12 - Stock Based Compensation - Compensation Expense (Details) - Stock Option Plan [Member] - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2020	Dec. 31, 2019
Compensation expense	$ (30)	$ 611	$ 1,003	$ 1,508
Research and Development Expense [Member]
Compensation expense	58	131	304	350
General and Administrative Expense [Member]
Compensation expense	174	386	706	959
Selling and Marketing Expense [Member]
Compensation expense	$ (262)	$ 94	$ (7)	$ 199

Note 13 - Supplemental Cash F_3

Note 13 - Supplemental Cash Flow Disclosure - Changes in Working Capital Items (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2020	Dec. 31, 2019
Receivables	$ 27	$ (237)	$ (20)	$ (10)
Inventory	(14)		(14)
Prepaid expenses	(23)	(1,074)	521	(518)
Trade and other payables	(1,999)	(696)	(5,891)	(2,342)
Increase (Decrease) in Working Capital	$ (2,009)	$ (2,007)	$ (5,404)	$ (2,870)

Note 13 - Supplemental Cash F_4

Note 13 - Supplemental Cash Flow Disclosure - Non-cash Transactions (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2020	Dec. 31, 2019
Equipment included in trade and other payables		$ 9		$ 9
ATM transaction costs included in trade and other payables	118		118
Shares issued as settlement				741
Fair value of derivative warrants liability reclassified to Equity		868		10,962
Interest payable included in trade and other payables		$ 31		$ 31

Note 14 - Commitments and Con_2

Note 14 - Commitments and Contingencies (Details Textual) - USD ($) $ in Thousands	Dec. 31, 2020	Oct. 31, 2020	Oct. 25, 2019
Chief Executive Officer [Member]
Retention Incentive Agreement, Continued Employment Until April 30, 2021 or Closing Transaction With Third Party		$ 100
Chief Executive Officer and Chief Operating Officer [Member]
Retention Incentive Agreement, Maximum Conditional Incentives		$ 125
RKO Supply Agreement [Member]
Purchase Obligation, Total			$ 3,100
Purchase Commitment, Remaining Minimum Amount Committed	$ 2,800

Note 16 - Subsequent Events (De

Note 16 - Subsequent Events (Details Textual) - USD ($)	1 Months Ended	3 Months Ended		9 Months Ended
	Jan. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2020	Dec. 31, 2019
Proceeds from Issuance of Common Stock		$ 19,745,000	$ 6,002,000	$ 24,955,000	$ 6,002,000
At-the-market Offering [Member]
Stock Issued During Period, Shares, New Issues (in shares)				65,900,000
Proceeds from Issuance of Common Stock, Net		$ 19,700,000		$ 24,800,000
At-the-market Offering [Member] | Subsequent Event [Member]
Stock Issued During Period, Shares, New Issues (in shares)	23,400,000
Proceeds from Issuance of Common Stock, Net	$ 7,900,000
Proceeds from Issuance of Common Stock	$ 8,100,000